>
Switch to:

Sorrento Therapeutics Debt-to-EBITDA

: -0.62 As of Dec. 2020
View and export this data going back to 2007. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sorrento Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $26.83 Mil. Sorrento Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $142.56 Mil. Sorrento Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2020 was $-273.42 Mil. Sorrento Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2020 was -0.62.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

NAS:SRNE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.62   Med: -0.69   Max: 0.19
Current: -0.61

-1.62
0.19

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sorrento Therapeutics was 0.19. The lowest was -1.62. And the median was -0.69.

NAS:SRNE's Debt-to-EBITDA is ranked lower than
99.99% of the 253 Companies
in the Biotechnology industry.

( Industry Median: 1.12 vs. NAS:SRNE: -0.61 )

Sorrento Therapeutics Debt-to-EBITDA Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Annual Data
Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 0.19 -1.59 -0.93 -0.61

Sorrento Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -1.08 -0.77 -0.69 -0.62

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Sorrento Therapeutics Debt-to-EBITDA Distribution

* The bar in red indicates where Sorrento Therapeutics's Debt-to-EBITDA falls into.



Sorrento Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sorrento Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(26.834 + 142.559) / -279.392
=-0.61

Sorrento Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(26.834 + 142.559) / -273.424
=-0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2020) EBITDA data.


Sorrento Therapeutics  (NAS:SRNE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sorrento Therapeutics Debt-to-EBITDA Related Terms


Sorrento Therapeutics Debt-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)